We are live on ! Find out more

SPHS

Sophiris Bio, Inc.

SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

14 hedge funds and large institutions have $998K invested in Sophiris Bio, Inc. in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New

Increased

Maintained

Reduced

Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

33% less funds holding

Funds holding: 21 → 14 (-7)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

95% less capital invested

Capital invested by funds: $18.2M → $998K (-$17.2M)

Holders

Holders Change

-7

Holders Change %

-33.33%

% of All Funds

0.37%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

Rank	Fund	Capital Flow
1	BI BVF Inc San Francisco, California	+$1.07M
2	GCM Gruss Capital Management New York	+$290K
3	VKH Virtu KCG Holdings New York	+$143K
4	Royal Bank of Canada Toronto, Ontario, Canada	+$19.7K
5	Citigroup New York	+$9.56K

Top Sellers

Rank	Fund	Capital Flow
1	T. Rowe Price Associates Baltimore, Maryland	-$4.72M
2	GPP Great Point Partners Greenwich, Connecticut	-$4.65M
3	AG Artal Group Luxembourg	-$2.93M
4	First Manhattan New York	-$1.04M
5	First Eagle Investment Management New York	-$733K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	BI 1 BVF Inc San Francisco, California	$573K	+$1.07M	+460,283	+77%
2	GCM 2 Gruss Capital Management New York	$264K	+$290K	+124,785	+34%
3	PAI 3 Palo Alto Investors Palo Alto, California	$103K	-$235K	-101,300	-35%
4	VKH 4 Virtu KCG Holdings New York	$33K	+$143K	+61,530	New
5	5 Bank of New York Mellon New York	$9K	+$6.96K	+3,000	+21%
6	6 Royal Bank of Canada Toronto, Ontario, Canada	$5K	+$19.7K	+8,500	+1,019%
7	7 UBS Group Zurich, Switzerland	$5K	+$20.7K	+8,940	New
8	8 Citigroup New York	$3K	+$9.56K	+4,119	+400%
9	9 Bank of Montreal Toronto, Ontario, Canada	$1K	–	–	–
10	BIM 10 BlackRock Investment Management Wilmington, Delaware	$1K	–	–	–
11	11 Wells Fargo San Francisco, California	$1K	–	–	–
12	12 T. Rowe Price Associates Baltimore, Maryland	–	-$4.72M	-1,609,928	Closed
13	GPP 13 Great Point Partners Greenwich, Connecticut	–	-$4.65M	-1,585,500	Closed
14	AG 14 Artal Group Luxembourg	–	-$2.93M	-1,000,000	Closed
15	15 First Manhattan New York	–	-$1.04M	-353,686	Closed
16	16 First Eagle Investment Management New York	–	-$733K	-250,000	Closed
17	17 Deutsche Bank Frankfurt Am Main Ge, Germany	–	-$216K	-73,861	Closed
18	18 TD Asset Management Toronto, Ontario, Canada	–	-$172K	-58,850	Closed
19	TRCT 19 Tower Research Capital (TRC) New York	–	-$930	-401	-80%
20	20 Bank of America Charlotte, North Carolina	–	+$44	+19	+50%

SPHS Hedge Fund Activity: Q4 2014 in Review

14 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q4 2014, worth a combined $998K — down 95% from $18.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SPHS and 2 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 6 added.

The largest buyer was BVF Inc, adding an estimated $1.07M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $4.72M sold.

14 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q4 2014, down from 21 in Q3 2014.
Funds reported $998K of Sophiris Bio, Inc. stock for Q4 2014, down 95% quarter-over-quarter.
2 funds opened new Sophiris Bio, Inc. positions in Q4 2014 and 8 closed out, a net change of -6 holders.
The largest Sophiris Bio, Inc. buyer in Q4 2014 was BVF Inc, an estimated $1.07M added.
The largest Sophiris Bio, Inc. seller in Q4 2014 was T. Rowe Price Associates, an estimated $4.72M sold.

Based on aggregated 13F filings for Q4 2014.

Sophiris Bio, Inc. SPHS